Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 5

Clinical relevance of maximal inspiratory pressure: determination in COPD exacerbation

Authors Voicu Tudorache, Cristian Oancea, Ovidiu Fira Mlădinescu

Published 22 April 2010 Volume 2010:5 Pages 119—123

DOI https://doi.org/10.2147/COPD.S9194

Review by Single-blind

Peer reviewer comments 2

Voicu Tudorache1, Cristian Oancea1, Ovidiu Fira Mlădinescu2

1Department of Pneumology, 2Department of Pathophysiology, Victor Babeş University of Medicine and Pharmacy, Timişoara, Romania

Abstract: Muscle dysfunction represents a pathophysiological feature of chronic obstructive pulmonary disease (COPD). Muscle impairment contributes to decreased effort capacity in these patients at least in the same proportion as pulmonary function limitation. Maximal inspiratory pressure (MIP) is a reliable, noninvasive parameter for assessing the respiratory muscle capacity. The aim of the present study was to determine the role of MIP in effort capacity decrease in COPD patients. MIP was measured in 121 COPD patients without hyperinflation (RV < 150%) together with the following investigations: body plethysmography, body impedance analysis, dynamometry, 6-minute walking test (6MWT), determination of SaO2 and serum levels of highly sensitive C-reactive protein (hsCRP). MIP (kPa) was significantly decreased in moderate-severe stages (6.19 ± 2.42, COPD II; 5.35 ± 2.49, COPD III; 4.56 ± 1.98, COPD IV vs 7.90 ± 2.61 in controls, P < 0.001), whereas the muscle force assessed by dynamometry was decreased only in advanced stages of disease (0.47 ± 0.12, COPD III; 0.41 ± 0.07, COPD IV vs 0.71 ± 0.16 in controls, P < 0.001). The values of MIP correlated (r = 0.53, P = 0.0003) with the distance walked in 6MWT. MIP may provide additive information concerning the general profile of muscle dysfunction in COPD patients.
Keywords: COPD, MIP, exacerbation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other articles by this author:

The impact of coping on the somatic and mental status of patients with COPD: a cross-sectional study

Papava I, Oancea C, Enatescu VR, Bredicean AC, Dehelean L, Romosan RS, Timar B

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:1343-1351

Published Date: 20 June 2016

Chronic obstructive pulmonary disease phenotypes and balance impairment

Voica AS, Oancea C, Tudorache E, Crisan AF, Fira-Mladinescu O, Tudorache V, Timar B

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:919-925

Published Date: 29 April 2016

Readers of this article also read:

Magnetic microparticle-based multimer detection system for the detection of prion oligomers in sheep

Lim K, Kim SY, Lee B, Segarra C, Kang S, Ju YR, Schmerr MJ, Coste J, Kim SY, Yokoyama T, An SSA

International Journal of Nanomedicine 2015, 10:241-250

Published Date: 9 September 2015

Ultrafast sonochemical synthesis of protein-inorganic nanoflowers

Batule BS, Park KS, Kim MI, Park HG

International Journal of Nanomedicine 2015, 10:137-142

Published Date: 25 August 2015

Reduction-responsive cross-linked stearyl peptide for effective delivery of plasmid DNA

Yao C, Tai Z, Wang X, Liu J, Zhu Q, Wu X, Zhang L, Zhang W, Tian J, Gao Y, Gao S

International Journal of Nanomedicine 2015, 10:3403-3416

Published Date: 8 May 2015

Peptide gH625 enters into neuron and astrocyte cell lines and crosses the blood–brain barrier in rats

Valiante S, Falanga A, Cigliano L, Iachetta G, Busiello RA, La Marca V, Galdiero M, Lombardi A, Galdiero S

International Journal of Nanomedicine 2015, 10:1885-1898

Published Date: 10 March 2015

Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients

Tzani P, Crisafulli E, Nicolini G, Aiello M, Chetta A, Clini E, Olivieri D

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:503-509

Published Date: 4 October 2011

Interleukin-6 and airflow limitation in chemical warfare patients with chronic obstructive pulmonary disease

Davood Attaran, Shahrzad M Lari, Mohammad Towhidi, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:335-340

Published Date: 30 September 2010

Influencing the decline of lung function in COPD: use of pharmacotherapy

Ekaterina S Gladysheva, Atul Malhotra, Robert L Owens

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:153-164

Published Date: 17 May 2010